This activity includes Powered by Patient videos.
Program Description
Vitiligo presents in patients as physical change in skin coloration and is thought to have an underlying autoimmune pathology. The significant alteration in skin appearance may leave patients with psychological and social burden as well as depression and social anxiety that affects relationships and quality of life. Current recommendations for patients who choose to treat vitiligo include phototherapy, topicals such as corticosteroids and calcineurin inhibitors, and the recently approved ruxolitinib cream. New disease targets have been identified that have led to the development and investigation of several novel drugs. As more is understood about the mechanisms of the underlying pathology of this condition, it is necessary that managed care professionals are equipped to develop coverage policies for vitiligo treatments. This program will review the challenges in the treatment of vitiligo, disease presentation and progression, and cost-effectiveness of current recommended treatments. A patient interview accompanying this program will provide additional insight on potential challenges, experience with treatment, and the involvement of pharmacists on their care team.
Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: August 29, 2023
Expiration date: October 29, 2023
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain current epidemiological data on vitiligo and its impact on patients' quality of life.
- Distinguish the efficacy and safety of common treatment options for vitiligo, including newly approved and emerging agents.
- Explore strategies to optimize treatment pathways for patients with vitiligo based on their clinical characteristics and medication profiles.
Dana McCormick, RPh, FAMCP
Pharmacy Director
BCBS of Texas
Grapevine, Texas
Nada Elbuluk, MD, MSc
Associate Professor of Clinical Dermatology
Director, Skin of Color & Pigmentary Disorders Program
University of Southern California Department of Dermatology
Keck School of Medicine
Los Angeles, California
Stephanie Cho, PharmD, BCPS
Content Development
Clinical Pharmacy Specialist in Dermatology
Kaiser Permanente Colorado
Castle Rock, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-328-L01-P. The activity is available for CE credit through October 29, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Content Development
Stephanie Cho, PharmD, BCPS has no relevant financial relationships with commercial interests to disclose.
Faculty
Dana McCormick, RPh, FAMCP, has no relevant financial relationships with commercial interests to disclose.
Nada Elbuluk, MD, MSc, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Avita Medical
Consultant: Avita Medical, Beiersdorf, Dior, Incyte, Scientis US, Unilever, VisualDx
Speaker: Beiersdorf, Dior, La Roche-Posay, Scientis US
Stock: VisualDx Stock Options
Other Support: Advisory Board: Allergan, Eli Lilly, Galderma, Incyte, Janssen, La Roche-Posay, L’Oreal, McGraw Hill, Pfizer
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms